We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Rebound Relapses After Ceasing Another Disease-Modifying Treatment in Patients With Multiple Sclerosis Are There Lessons to Be Learned?

Rhonda Voskuhl, MD1
[+] Author Affiliations
1Department of Neurology, University of California, Los Angeles
JAMA Neurol. 2016;73(7):775-776. doi:10.1001/jamaneurol.2016.0934.
Text Size: A A A
Published online


“Do no harm” is the timeless tenet of the Hippocratic Oath. It applies not only to how patients tolerate prescribed treatments but also to how they tolerate treatments after discontinuation. The sum of both events must be considered in the overall risk-benefit ratio before starting any given treatment.

The article by Hatcher et al1 published in this issue of JAMA Neurology describes a rebound in multiple sclerosis (MS) relapses after ceasing fingolimod treatment. Rebound occurred in 5 of 46 patients (10.9%) at their center, with additional reports identified by the authors’ literature search. Rebounds in relapses were clinically severe and accompanied by magnetic resonance imaging lesion activity that surpassed the level of activity before starting treatment. The first step during postmarketing experience is to report adverse events to increase awareness and provide a rationale for a registry to be created to establish frequency. This is addressed by Hatcher et al.1 The next step is to understand why rebound is occurring in order to prevent it from happening to other patients in the future. Finally, a discussion of the altered risk-benefit ratio of fingolimod within the context of currently evolving schools of thought regarding disease-modifying treatments in relapsing-remitting MS (RRMS) is warranted.

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles